Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
McKesson sale of minority stake in Medical-Surgical Solutions to Apollo
We are advising McKesson on the transaction
JATT II Acquisition $60 million SPAC IPO
We advised the sole bookrunning manager in connection with the IPO
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings
Adagene $70 million registered direct offering
We advised Adagene on the offering
AN2 Therapeutics $80 million at-the-market offering
We advised the sales agent on the offering
Carestream Health debt refinancing transaction
We advised an ad hoc group of lenders on the transaction
CytomX Therapeutics $250 million follow-on offering
We advised the representatives of the underwriters on the offering
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
CRISPR Therapeutics $600 million convertible notes offering
We advised the initial purchasers on the offering
Integer Holdings cooperation agreement with Irenic Capital Management
We are advising Integer on its cooperation agreement with Irenic Capital